Clinuvel Pharmaceuticals (ASX:CUV) said it will repurchase a maximum of 1.5 million ordinary fully-paid shares as part of an on-market buyback, according to a Thursday Australian bourse filing.
The repurchases are expected to start on April 10 and will run for 12 months, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。